Tahir Amin, co-founder and director of IP at the U.S.-based Initiative for Medicines, Access & Knowledge (I-MAK), told BNA April 1. “This is important as companies craft patent applications in a way to write follow up ones to get 3-5 years more exclusivity,” he said.
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.